DPP4/CD32b/NF-κB Circuit: A Novel Druggable Target for Inhibiting CRP-Driven Diabetic Nephropathy

Patrick Ming-Kuen Tang,Ying-Ying Zhang,Jessica Shuk-Chun Hung,Jeff Yat-Fai Chung,Xiao-Ru Huang,Ka-Fai To,Hui-Yao Lan

DOI: https://doi.org/10.1016/j.ymthe.2020.08.017

IF: 12.91

2021-01-01

Molecular Therapy

Abstract:<p>Diabetic nephropathy (DN) is a major cause of end-stage renal disease, but treatment remains ineffective. C-reactive protein (CRP) is pathogenic in DN, which significantly correlated with dipeptidyl peptidase-4 (DPP4) expression in diabetic patients with unknown reason. Here, using our unique CRP^tg-db/db mice, we observed human CRP markedly induced renal DPP4 associated with enhanced kidney injury compared to db/db mice. Interestingly, linagliptin, an FDA-approved specific DPP4 inhibitor, effectively blocked this CRP-driven DN in the CRP^tg-db/db mice. Mechanistically, CRP evoked DPP4 in cultured renal tubular epithelial cells, where CD32b/NF-κB signaling markedly enriched p65 binding on DPP4 promoter region to increase its transcription. Unexpectedly, we further discovered that CRP triggers dimerization of DPP4 with CD32b at protein level, forming a novel DPP4/CD32b/NF-κB signaling circuit for promoting CRP-mediated DN. More importantly, linagliptin effectively blocked the circuit, thereby inhibiting the CRP/CD32b/NF-kB-driven renal inflammation and fibrosis. Thus, DPP4 may represent as a precise druggable target for CRP-driven DN.</p>

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology